Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
Status:
Terminated
Trial end date:
2017-08-14
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to study the safety of ADCETRISTM (brentuximab
vedotin) in patients with Hodgkin lymphoma or ALCL who have had an allogeneic or
haploidentical stem cell transplant. Another goal of this study is to learn if brentuximab
vedotin can help to prevent the disease from coming back.